RenalytixAI: KidneyIntelX

Interpace Pharma solutions, a subsidiary of Interpace Biosciences has launched its RNAscope in situ hybridization (ISH) assay. The firm said RNAscope ISH uses "double Z" probes that simultaneously offer signal amplification and background noise control. Single-molecule visualization of the assay produces quantitative RNA expression and cell-specific expression in intact tissue architecture. The firm said that RNAscope ISH can be used to streamline immune checkpoint target identification, visualize in vivo delivery of CAR-T therapeutic products, and distinguish therapeutic gene sequence from endogenous transcripts selection, even when there is no known or validated antibody. 

Synthego has launched Eclipse, a CRISPR-based high-throughput cell engineering platform. The automated platform is cell-type agnostic, optimizes transfection, and provides end-to-end data tracking software. Applications include disease modeling, drug target identification and validation, and cell therapy manufacturing.

Bio-Techne has launched the Cultrex UltiMatrix Reduced Growth Factor Basement Membrane Extract (UltiMatrix RGF BME), an extracellular matrix hydrogel for culturing organoids and pluripotent stem cells. UltiMatrix RGF BME is a dependable, high-concentration cell scaffolding matrix with compositional and physical properties specifically designed for generating advanced 2D and 3D cell culture models. It features increased total protein content, optimized extracellular matrix protein composition, high levels of entactin, and improved tensile strength while reducing the dependency on supplemental growth factors, Bio-Techne said.

Lincoln, Nebraska-based Materials and Machines Corporation, also known as MatMaCorp, has launched a rapid handheld molecular testing instrument called MY Real-Time Analyzer, or MYRTA, that performs PCR amplification or isothermal amplification and simultaneous real-time fluorescence detection. The device weighs less than one pound, can be held in one hand during operation, and can detect DNA or RNA targets within one hour, according to MatMaCorp. MYRTA can also process one sample with up to three different tests, and provides near quantitative information, including a Ct value.

Thermo Fisher Scientific has launched the Thermo Scientific KingFisher Apex Purification System, a high-throughput sample purification instrument for automated extraction of DNA, RNA, proteins, and cells from various sample types. The instrument is easy to use, saves time, and returns consistent results, the company said.

The KingFisher Apex enables nucleic acid, protein, and cell isolation while allowing users to customize protocols directly from the instrument to provide flexible, reproducible, and fast sample preparation without additional expense or complexity. It automates much of the work associated with the preparation of high-quality nucleic acids and proteins, can process 24 to 96 samples in 25 to 65 minutes, and elutes in volumes as low as 10 µL. 

The system can be used in combination with any of the Applied Biosciences MagMAX Isolation kits, as well as with Invitrogen Dynabeads Magnetic Separation products, Thermo Fisher said. Additional features include heating and cooling controls to maintain sample integrity, dual UV lights to safeguard against contamination, cloud-enabled access to up-to-date validated protocols, dual magnets to support small and large volume ranges, and the ability to elute in storage tubes to revisit samples later. It also has a touchscreen to allow users to write, edit, and run protocols directly on the instrument.

Tempus has launched an amplicon-based, high-throughput next-generation sequencing assay for the detection of SARS-CoV-2 virus mutations. The research-use-only assay includes primers designed to detect mutations and to characterize SARS-CoV-2 RNA.

Horizon Discovery, a PerkinElmer company, has launched a new family of CRISPR modulation reagents for CRISPR interference, enabling researchers a better understanding of the biological pathways, processes, and pathologies of disease by repressing genes at the transcription level, and leading to new therapies.

The new reagents include what Horizon Discovery said are the first commercially available synthetic single guide RNAs for CRISPRi. Also included is a dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats. The new technologies gives researchers the ability to repress genes in almost all cell lines, across any length of time, and at any scale, Horizon Discovery said.